By IDSE News Staff
Ceftolozane-tazobactam (Zerbaxa, Merck & Co.) met the prespecified primary end points that demonstrated noninferiority to meropenem in a recent phase 3 trial in patients with pneumonia.
The prospective, randomized, double-blind, multicenter, noninferiority, phase 3 ASPECT-NP study assessed the safety and efficacy of ceftolozane-tazobactam compared with meropenem in 726 adult patients diagnosed with either hospital-acquired bacterial pneumonia or ventilator-associated